Clinical Trial Update: Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab plus ipilimumab as neoadjuvant therapy for hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: COMPLETED